Newsroom | Breyer Capital

Breyer Capital Catalyzes the Future of AI-Driven Medicine at Harvard Medical School

Artificial intelligence is no longer a distant prospect in medicine—it is reshaping patient care, biomedical discovery, and healthcare efficiency. Leading medical institutions must prepare future leaders to harness AI in tackling the most pressing challenges in biomedicine. Harvard Medical School’s Department of Biomedical Informatics (DBMI) is rising to this challenge with the Artificial Intelligence in Medicine (AIM) PhD track—a program designed to cultivate physician-scientists and computational biologists who will redefine AI-driven healthcare.

Breyer Capital, a global leader in venture capital, has made a transformative commitment to this program, reinforcing its role as a top investor in healthcare AI. With a distinguished track record of backing computational biomedical companies at their earliest stages, Breyer Capital continues to shape medicine’s future by supporting exceptional talent and cutting-edge research. This investment will provide comprehensive training for students in the AIM PhD track over the next several years.

Read Full Story >

CNBC Interview – Large Quantitative Models

Jack Hidary, SandboxAQ, and Jim Breyer, Breyer Capital founder and CEO, join ‘Money Movers’ to discuss what Sandbox is and the technological edge the company has, why Breyer is so excited about the large quantitative model, and how to think about the opportunity for quantitative AI.

Watch Interview >

Jim Breyer’s Bloomberg Interview from Davos

Breyer Capital founder and CEO Jim Breyer speaks with Lisa Abramowicz at the World Economic Forum’s annual meeting in Davos, Switzerland. (Source: Bloomberg)

Watch Interview >

Broad Institute cofounder Schreiber leaves to launch new research institution Arena BioWorks

Called Arena BioWorks, the new organization has been in the works for several years. For Schreiber, the seeds were planted in early 2020. He and Thomas Cahill, cofounder and managing director of the investment firm Newpath Partners, had formed a 12-person group called Scientists to Stop COVID-19.

When Schreiber moved on from the pandemic-era project, he took that lesson with him. He had in mind to set up an organization not unlike the Broad Institute, but with a key difference. It would be funded wholly by private financiers—from the research stage to company formation and potential commercialization.

Others quickly came on board. Stephen Pagliuca, a healthcare investor and co-owner of the Boston Celtics who’d previously backed the Pagliuca Life Lab at Harvard University, became “intimately involved” with the planning process, Schreiber says. Pagliuca helped orchestrate a meeting in December 2021 with Jim Breyer, founder and CEO of Breyer Capital and an early backer of Facebook, and Michael Dell, the founder of Dell Technologies. Both executives agreed to support the project within 25 min.

Read Full Story >

Jim Breyer joins ‘Squawk Box’ from WEF

Breyer Capital founder and CEO Jim Breyer joins ‘Squawk Box’ to discuss the impact of AI on the VC landscape, how AI can change health care, and more.

Watch Interview >

Jim Breyer Italian Interview on AI: Riformista

Read Full Story >